Our Divided Patent System
暂无分享,去创建一个
In this comprehensive new study, we evaluate all substantive decisions rendered by any court in every patent case filed in 2008 and 2009 — decisions made between 2009 and 2013. We assess the outcome of litigation by technology and industry. We relate the outcomes of those cases to a host of variables, including variables related to the parties, the patents, and the courts in which those cases were litigated. We find dramatic differences in the outcomes of patent litigation by both technology and industry. For example, owners of patents in the pharmaceutical industry fare much better in dispositive litigation rulings than do owners of patents in the computer & electronics industry, and chemistry patents have much greater success in litigation than their software or biotech counterparts. Our results provide an important window into both patent litigation and the industry-specific battles over patent reform. And they suggest that the traditional narrative of industry-specific patent disputes, which pits the IT industries against the life sciences, is incomplete.
[1] 김형건. 인간 유전자와 유전자 진단 방법의 특허대상발명 여부 -Association for Molecular Pathology v. United States Patent and Trademark Office 판결에 대한 평석- , 2010 .
[2] Heidi L. Williams,et al. Intellectual Property Rights and Innovation: Evidence from the Human Genome , 2013, Journal of Political Economy.